In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice

Marilena Manea, J. Tóvári, Miguel Tejeda, Ákos Schulcz, Bence Kapuvári, B. Vincze, G. Mező

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Targeted cancer chemotherapy is a novel approach developed for the specific delivery of anticancer drugs. Tumour targeting can be achieved by combining a chemotherapeutic agent with a targeting moiety that recognizes tumour-specific or highly expressed receptors on cancer cells. We used the gonadotropin- releasing hormone-III (GnRH-III) as a targeting moiety to which the chemotherapeutic agent daunorubicin (Dau) was attached through an oxime bond either directly or by inserting a GFLG tetrapeptide spacer. The in-vivo toxicity of Dau-GnRH-III derivative conjugates was evaluated on healthy BDF-1 female mice, and their tumour growth inhibitory effect was determined on C26 murine and HT-29 human colon carcinoma-bearing mice. Both oxime bond-containing conjugates were well tolerated and exerted significant antitumour activity on C26 colon carcinoma-bearing mice at a dose of 30 mg Dau content in conjugate/kg body weight. Furthermore, the conjugates inhibited the tumour growth more than the free drug at a dose that was still not toxic. Similar tumour growth inhibitory effects were obtained on HT-29 human colon carcinoma-bearing mice using three treatments with 15 mg Dau content in conjugate/kg. The tumour growth inhibitions according to the tumour volume and the tumour weight were 44/41% and 58/50%, respectively. Considering the results, both of the investigated Dau-GnRH-III derivative conjugates were well tolerated and had significant antitumour effect on colon carcinoma-bearing mice.

Original languageEnglish
Pages (from-to)90-97
Number of pages8
JournalAnti-Cancer Drugs
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Daunorubicin
Colon
Carcinoma
Neoplasms
Oximes
Growth
Tumor Burden
gonadotropin-releasing hormone-III
Poisons
Pharmaceutical Preparations
Body Weight
Drug Therapy

Keywords

  • colon cancer
  • daunorubicin-GnRH-III derivative conjugates
  • gonadotropin-releasing hormone-III
  • in-vivo antitumour activity
  • in-vivo toxicity
  • oxime bond
  • targeted cancer chemotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice. / Manea, Marilena; Tóvári, J.; Tejeda, Miguel; Schulcz, Ákos; Kapuvári, Bence; Vincze, B.; Mező, G.

In: Anti-Cancer Drugs, Vol. 23, No. 1, 01.2012, p. 90-97.

Research output: Contribution to journalArticle

Manea, Marilena ; Tóvári, J. ; Tejeda, Miguel ; Schulcz, Ákos ; Kapuvári, Bence ; Vincze, B. ; Mező, G. / In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice. In: Anti-Cancer Drugs. 2012 ; Vol. 23, No. 1. pp. 90-97.
@article{471d776bb92d4028b12fa07171acb7f6,
title = "In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice",
abstract = "Targeted cancer chemotherapy is a novel approach developed for the specific delivery of anticancer drugs. Tumour targeting can be achieved by combining a chemotherapeutic agent with a targeting moiety that recognizes tumour-specific or highly expressed receptors on cancer cells. We used the gonadotropin- releasing hormone-III (GnRH-III) as a targeting moiety to which the chemotherapeutic agent daunorubicin (Dau) was attached through an oxime bond either directly or by inserting a GFLG tetrapeptide spacer. The in-vivo toxicity of Dau-GnRH-III derivative conjugates was evaluated on healthy BDF-1 female mice, and their tumour growth inhibitory effect was determined on C26 murine and HT-29 human colon carcinoma-bearing mice. Both oxime bond-containing conjugates were well tolerated and exerted significant antitumour activity on C26 colon carcinoma-bearing mice at a dose of 30 mg Dau content in conjugate/kg body weight. Furthermore, the conjugates inhibited the tumour growth more than the free drug at a dose that was still not toxic. Similar tumour growth inhibitory effects were obtained on HT-29 human colon carcinoma-bearing mice using three treatments with 15 mg Dau content in conjugate/kg. The tumour growth inhibitions according to the tumour volume and the tumour weight were 44/41{\%} and 58/50{\%}, respectively. Considering the results, both of the investigated Dau-GnRH-III derivative conjugates were well tolerated and had significant antitumour effect on colon carcinoma-bearing mice.",
keywords = "colon cancer, daunorubicin-GnRH-III derivative conjugates, gonadotropin-releasing hormone-III, in-vivo antitumour activity, in-vivo toxicity, oxime bond, targeted cancer chemotherapy",
author = "Marilena Manea and J. T{\'o}v{\'a}ri and Miguel Tejeda and {\'A}kos Schulcz and Bence Kapuv{\'a}ri and B. Vincze and G. Mező",
year = "2012",
month = "1",
doi = "10.1097/CAD.0b013e32834bb6b4",
language = "English",
volume = "23",
pages = "90--97",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice

AU - Manea, Marilena

AU - Tóvári, J.

AU - Tejeda, Miguel

AU - Schulcz, Ákos

AU - Kapuvári, Bence

AU - Vincze, B.

AU - Mező, G.

PY - 2012/1

Y1 - 2012/1

N2 - Targeted cancer chemotherapy is a novel approach developed for the specific delivery of anticancer drugs. Tumour targeting can be achieved by combining a chemotherapeutic agent with a targeting moiety that recognizes tumour-specific or highly expressed receptors on cancer cells. We used the gonadotropin- releasing hormone-III (GnRH-III) as a targeting moiety to which the chemotherapeutic agent daunorubicin (Dau) was attached through an oxime bond either directly or by inserting a GFLG tetrapeptide spacer. The in-vivo toxicity of Dau-GnRH-III derivative conjugates was evaluated on healthy BDF-1 female mice, and their tumour growth inhibitory effect was determined on C26 murine and HT-29 human colon carcinoma-bearing mice. Both oxime bond-containing conjugates were well tolerated and exerted significant antitumour activity on C26 colon carcinoma-bearing mice at a dose of 30 mg Dau content in conjugate/kg body weight. Furthermore, the conjugates inhibited the tumour growth more than the free drug at a dose that was still not toxic. Similar tumour growth inhibitory effects were obtained on HT-29 human colon carcinoma-bearing mice using three treatments with 15 mg Dau content in conjugate/kg. The tumour growth inhibitions according to the tumour volume and the tumour weight were 44/41% and 58/50%, respectively. Considering the results, both of the investigated Dau-GnRH-III derivative conjugates were well tolerated and had significant antitumour effect on colon carcinoma-bearing mice.

AB - Targeted cancer chemotherapy is a novel approach developed for the specific delivery of anticancer drugs. Tumour targeting can be achieved by combining a chemotherapeutic agent with a targeting moiety that recognizes tumour-specific or highly expressed receptors on cancer cells. We used the gonadotropin- releasing hormone-III (GnRH-III) as a targeting moiety to which the chemotherapeutic agent daunorubicin (Dau) was attached through an oxime bond either directly or by inserting a GFLG tetrapeptide spacer. The in-vivo toxicity of Dau-GnRH-III derivative conjugates was evaluated on healthy BDF-1 female mice, and their tumour growth inhibitory effect was determined on C26 murine and HT-29 human colon carcinoma-bearing mice. Both oxime bond-containing conjugates were well tolerated and exerted significant antitumour activity on C26 colon carcinoma-bearing mice at a dose of 30 mg Dau content in conjugate/kg body weight. Furthermore, the conjugates inhibited the tumour growth more than the free drug at a dose that was still not toxic. Similar tumour growth inhibitory effects were obtained on HT-29 human colon carcinoma-bearing mice using three treatments with 15 mg Dau content in conjugate/kg. The tumour growth inhibitions according to the tumour volume and the tumour weight were 44/41% and 58/50%, respectively. Considering the results, both of the investigated Dau-GnRH-III derivative conjugates were well tolerated and had significant antitumour effect on colon carcinoma-bearing mice.

KW - colon cancer

KW - daunorubicin-GnRH-III derivative conjugates

KW - gonadotropin-releasing hormone-III

KW - in-vivo antitumour activity

KW - in-vivo toxicity

KW - oxime bond

KW - targeted cancer chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=82555166976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82555166976&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e32834bb6b4

DO - 10.1097/CAD.0b013e32834bb6b4

M3 - Article

VL - 23

SP - 90

EP - 97

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 1

ER -